Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览7

暂无评分

摘要

FES PET is an FDA-approved imaging biomarker. Like IHC, FES positivity predicts clinical benefit of endocrine therapy. In addition, FES measures the target activity in endocrine agent drug development. A recent study found that whole body tumor heterogeneity of expression predicts clinical benefit, and serial FES monitors ER blockade and post treatment release.

查看译文

关键词

evolving breast cancer treatments,molecular imaging,breast cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要